Nancy Lin
Has grant
Associate Professor of Medicine
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
ctDNA Guided Care in Patients with Metastatic Breast Cancer
Open Date: 2026-10-01
Close Date: 2028-09-30
Grant: Close
Improving Therapeutic Options for Patients with Breast Cancer and Central Nervous System Metastases
Open Date: 2023-10-01
Close Date: 2024-09-30
Grant: Close
Improving Therapeutic Options for Patients with Breast Cancer Brain Metastases
Open Date: 2022-10-01
Close Date: 2023-09-30
Articles (21)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Importance Brain metastases portend poor prognosis in patients with metastatic breast cancer (MBC). Designing treatment and prevention clinical trials requires knowledge of brain metastases incidence with each line of therapy. Objectives We assessed the prevalence and cumulative incidence of brain metastases in a large MBC patient cohort by subtype and line of therapy, and the impact of HER2-low expression on prevalence. Design, Setting and Outcomes We analyzed brain metastases prevalence in patients with MBC in a nationwide electronic health record-derived de-identified database. The primary outcome was first diagnosis of brain metastases. We estimated prevalence and incidence of brain metastases by MBC subtype, including HER2-low and therapy line. We used the cumulative incidence function to estimate brain metastases risk in patients without brain metastases at initiation of systemic therapy. All P-values are 2-sided, and a P-value ≤.05 indicates statistical significance. Results Among 18 075 patients with MBC, 1102 (6.1%) had at least 1 brain metastasis at first-line therapy initiation. For the remaining 16 973 patients, cumulative incidence of brain metastases at 60 months was 10% in patients with hormone receptor-positive (HR+)/HER2− disease, 23% for HR+/HER2+ disease, 34% for HR−/HER2+ disease, and 22% for triple-negative breast cancer (TNBC). HER2-low expression within HR+/HER2− and TNBC subtypes had no impact on brain metastases incidence. Brain metastases prevalence increased per line of therapy for patients with all breast cancer subtypes. Conclusions Brain metastases incidence increases per line of therapy for every MBC subtype. The HER2-low biomarker does not impact brain metastases incidence within historical subtypes.
Year:
2025
Background The phase III RxPONDER trial has affected treatment for node-positive (1-3), hormone receptor-positive, HER2-negative breast cancer with a 21-gene recurrence score (RS) less than 26. We investigated how these findings apply to different racial and ethnic groups within the trial. Methods The trial randomly assigned women to endocrine therapy (ET) or to chemotherapy plus ET. The primary clinical outcome was invasive disease-free survival (IDFS), with distant relapse-free survival (DRFS) as a secondary outcome. Multivariable Cox models were used to evaluate the association between race/ethnicity and survival outcomes, adjusting for clinicopathological characteristics, RS, and treatment. Results A total of 4048 women with self-reported race/ethnicity were included: Hispanic (15.1%), non-Hispanic Black (NHB) (6.1%), Native American/Pacific Islander (0.8%), Asian (8.0%), and non-Hispanic White (NHW) (70%). No differences in RS distribution, tumor size, or number of positive nodes were observed by race/ethnicity. Relative to NHWs, IDFS was worse for NHB participants (5-year IDFS 91.6% vs 87.1%, HR = 1.37; 95% CI = 1.03 to 1.81) and better for Asians (91.6% vs 93.9%, HR = 0.64; 95% CI = 0.46 to 0.91). Relative to NHW, DRFS was worse for NHB participants (5-year DRFS 95.8% vs 91.0%, HR = 1.65; 95% CI = 1.17 to 2.32) and better for Asians (95.8% vs 96.7%, HR = 0.59; 95% CI = 0.37 to 0.95). Adjusting for clinical characteristics, particularly body mass index, diminished the effect of race on outcomes. Chemotherapy treatment efficacy did not differ by race/ethnicity. Conclusions NHB women had worse clinical outcomes compared with NHWs in the RxPONDER trial despite similar RS and comparable treatment. Our study emphasizes the persistent racial disparities in breast cancer outcomes while highlighting complex interactions among contributing factors. Trial Registration ClinicalTrials.gov: NCT01272037.
Year:
2025
Purpose: Cyclin-dependent kinase 4/6 inhibitors can significantly extend survival when given in combination with endocrine therapy in patients with hormone receptor–positive metastatic breast cancer. However, their activity has been relatively underexplored in patients with metastatic triple-negative breast cancer (mTNBC). Patients and Methods: We conducted a single-arm phase II study of abemaciclib monotherapy in patients with Rb-positive mTNBC. Patients were treated with abemaciclib 200 mg orally twice daily until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was the objective response rate; secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate, disease control rate, and safety and tolerability. Results: A total of 27 patients were enrolled before the trial was closed early because of slow accrual. Patients had received a median of two lines of systemic therapy in the metastatic setting prior to enrollment. After a median follow-up of 28.5 months, the objective response rate was 0%, the clinical benefit rate was 14.8%, and the disease control rate was 22.2%. The median PFS was 1.94 months (95% confidence interval, 1.84–11.47), and the median OS was 8.44 months (95% confidence interval, 4.57–15.57). Median PFS and OS did not differ significantly based on androgen receptor and PD-L1 status. Pretreatment gene expression profiling of tumor tissue provided some hypothesis-generating insights into biological features associated with clinical benefit in this study. The most common treatment-related adverse events of grade 2 or higher were diarrhea (40.7%), neutropenia (40.7%), anemia (29.6%), and nausea (29.6%). Conclusions: Abemaciclib monotherapy did not show clinical activity in patients with pretreated Rb-positive mTNBC.
Year:
2025
Supplementary Figure 2 displays the relationship between the week 8 CM level and the change in CM level (Week 8 – baseline). Figure S4B and C use box plots to display the relationship between disease status at first restaging and week 8 CM level or change in CM level (Week 8 – baseline).
Year:
2025
Supplementary figure 5 displays time updated ROC curves for (A) CM level at week 8, (B) Change in CM level (Week8 – Week4) and (C) the Combination of week 8 CM level and Change in CM level (Week 8-Week 4) using linear discriminant analysis.
Year:
2025
PURPOSE Prognostic assessment in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC) remains challenging, given relatively low rates of disease progression. Modern artificial intelligence (AI)–based techniques have provided advanced prognostic tools in cancer. PATIENTS AND METHODS The Artera multimodal AI (MMAI) platform, using digital histopathology and clinical data, was applied to develop and test a prognostic risk assessment algorithm in HR+/HER2– EBC. Hematoxylin and eosin (H&E) slides from pretreatment breast biopsy and surgical specimens were digitized from the WSG PlanB and ADAPT trials. Patients with available images and complete data (n = 5,259) were stratified by trial, treatment, and distant metastasis (DM) into training (development: 60%) and internal validation (holdout: 40%) cohorts. The algorithm provided prognostic DM risk scores on the basis of image data and clinical variables (age, T and N stages, and tumor size). Univariable and multivariable Fine-Gray models were used to assess performance on the test cohort; subdistribution hazard ratios (sHR) are reported per standard deviation increase of the model scores. Prespecified prognostic subgroups for analysis were defined by nodal status, menopausal status, and tumor grade. RESULTS The trained MMAI score was significantly associated with risk of DM in the test cohort (sHR, 2.3 [95% CI, 2.0 to 2.8]) as a whole and across subgroups. The score remained significant (sHR, 2.2 [95% CI, 1.7 to 2.8]) after adjusting for clinical prognostic factors. The MMAI image component alone had significant prognostic value (sHR, 1.6 [95% CI, 1.3 to 1.9]) in the test cohort; it also had significant prognostic value separately within the G2 and G3 subgroups, with sHR of 1.5 per standard deviation increase, and in most of the other predefined clinical subgroups. CONCLUSION MMAI using digital pathology from H&E slides provides enhanced prognostic quality in HR+/HER2– EBC and could help to advance personalized breast cancer management.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (41)
Alessandro Di Federico
University of Bologna
Mark Awad
Chief, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
Isabel T Rubio
Clinica Universidad de Navarra
Anne M May
University Medical Center Groningen
Toni Choueiri
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Charles Edward Geyer Jr
Professor of Medicine in Division of Hematology/Medical Oncology
University of Pittsburgh
Lisa Anne Carey
Deputy Director for Clinical Science
University of North Carolina at Chapel Hill
Chiara Corti
Dana-Farber Cancer Institute
Yara G Abdou
University of North Carolina at Chapel Hill
Morag Park
McGill University
Carey Anders
Assistant Director of Clinical Research
Duke University
Julie Gralow
Chief Medical Officer
-
Andrew D Cherniack
Group Leader
Dana-Farber Cancer Institute
Rita Nanda
Associate Professor of Medicine; Director Breast Oncology
University of Chicago
Nadia Harbeck
-
Hope Rugo
Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology
City Of Hope National Medical Center
Michael Bates
-
Eddy Saad
Dana-Farber Cancer Institute
Scott Rodig
Professor of Pathology
Beth Israel Deaconess Medical Center
Antonio Giordano
Dana-Farber Cancer Institute
Neal Lindeman
Vice Chair, Molecular Pathology and Laboratory Medicine
Weill Cornell Medicine
Peter Sorger
Otto Krayer Professor of Systems Pharmacology
Harvard Medical School
Glenn Hanna
Dana-Farber Cancer Institute
William J. Muller
Professor
McGill University
Brittany Bychkovsky
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Elizabeth Mittendorf
Harvard University
Sara Hurvitz
Professor, Division Head
Washington University School of Medicine
Antonio Wolff
Professor of Oncology
Johns Hopkins University
James Ingle
Mayo Clinic Rochester
Lesley Fallowfield
Director, Professor of Psycho-oncology
University of Sussex
Sandra M. Swain
Georgetown University Medical Center
Sarah Sammons
Assistant Professor
Dana-Farber Cancer Institute
Shom Goel
University of Melbourne
Priya Kumthekar
Northwestern Medicine
Kala Visvanathan
Professor
Johns Hopkins University
Michel L. Tremblay
James McGill Distinguished Professor
McGill University
Erica Mayer
Dana-Farber Cancer Institute
Filipa Lynce
Dana-Farber Cancer Institute
Eric Winer
Director
Yale University
Saraswati Sukumar
Professor
Johns Hopkins University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.